index.php

Topic: glioblastoma

by George Lundberg, MDOnly rarely does an experienced editor get a spine tingle from a new paper. For the first time ever, today, I predict that a Nobel Prize for medicine will be awarded to J. Mart ... more

Researchers from the University of Massachusetts Medical School have identified a novel approach of combining chemotherapy with a targeted therapy to decrease the recurrence of glioblastoma multiforme ... more

Researchers from the University of Massachusetts Medical School have identified a novel approach of combining chemotherapy with a targeted therapy to decrease the recurrence of glioblastoma multiforme ... more

PHILADELPHIA — Researchers from the University of Massachusetts Medical School have identified a novel approach of combining chemotherapy with a targeted therapy to decrease the recurrence of gliobla ... more

Researchers have identified a novel approach of combining chemotherapy with a targeted therapy to decrease the recurrence of glioblastoma multiforme, the most common and aggressive brain tumor. ... more

Milwaukee Journal Sentinel: "Paula Oertel, whose brain tumor disappeared for nine years while she was on an expensive drug and returned after she temporarily lost her insurance coverage, has died as a ... more

Malignant gliomas are the most common subtype of primary brain tumor - and one of the deadliest. Even as doctors make steady progress treating other types of solid tumor cancers, from breast to prosta ... more

Malignant gliomas are the most common subtype of primary brain tumor - and one of the deadliest. Even as doctors make steady progress treating other types of solid tumor cancers, from breast to prosta ... more

Malignant gliomas are the most common subtype of primary brain tumor €“ and one of the deadliest. Even as doctors make steady progress treating other types of solid tumor cancers, from breast to pros ... more

Glioblastoma multiforme is the most common form of brain cancer; being an extremely serious type of the disease as currently, on diagnosis, the chances of survival of the patient is less than a year. ... more

Glioblastoma multiforme is the most common form of brain cancer; being an extremely serious type of the disease as currently, on diagnosis, the chances of survival of the patient is less than a year. ... more

A major breakthrough in how to target and destroy the most malignant and aggressive brain cancer cells has been made by researchers at Wake Forest University Baptist Medical Center. Scientists have id ... more

A major breakthrough in how to target and destroy the most malignant and aggressive brain cancer cells has been made by researchers. Scientists have identified a way to target and destroy glioblastoma ... more

WINSTON-SALEM, N.C. – Tuesday, Aug. 3, 2010 – A major breakthrough in how to target and destroy the most malignant and aggressive brain cancer cells has been made by researchers at Wake Forest Unive ... more

Researchers at Boston College, MA, have found that reducing calorie intake can restrict the growth and spread of brain cancer. Writing in ASN NEURO, Laura Shelton and colleagues report success with mi ... more

Researchers at Duke University Medical Center have identified a mechanism that could explain how patients move into the worst phase of chronic myelogenous leukemia (CML). This same molecular pathway m ... more

In their latest research, scientists of the Max Delbruck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have demonstrated how the brain's own stem cells and precursor cells control the grow ... more

In their latest research, scientists of the Max Delbruck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have demonstrated how the brain's own stem cells and precursor cells control the grow ... more

Scientists in Germany have demonstrated how the brain's own stem cells and precursor cells control the growth of glioblastomas. Of all brain tumors, glioblastomas are among the most common and most ag ... more

Large-scale cancer genome characterization projects on glioblastoma, lung, colon, pancreas, and breast cancers have been undertaken. One is now available online on prostate cancer. Medscape Medical ... more

The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by The Cancer ... more

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) through LRP-1 targeting, announced that complete phase 1/2 ... more

Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented as a late breaking abstract during the Neuro-Oncolo ... more

Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented as a late breaking abstract during the Neuro-Oncolo ... more

ImmunoCellular Therapeutics, Ltd... ... more

A brain cancer vaccine from Immunocellular Therapeutics has yielded positive results in a small Phase I clinical trial, reports Fierce Biotech. The study involved only 16 patients with glioblastoma m ... more

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant i ... more

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant i ... more

UPDATE 1-AstraZeneca won't file Recentin for colon cancer LONDON, May 28 (Reuters) - AstraZeneca (AZN.L) dropped plans to file its experimental cancer drug Recentin as a first-line treatment fo ... more

UPDATE 1-AstraZeneca won't file Recentin for colon cancer LONDON, May 28 (Reuters) - AstraZeneca (AZN.L) dropped plans to file its experimental cancer drug Recentin as a first-line treatment fo ... more

Exelixis, Inc. (NASDAQ:EXEL) reported promising interim data from an ongoing phase 2 trial of XL184 in patients with recurrent glioblastoma (GB), the most common and aggressive form of brain cancer. D ... more

Exelixis, Inc. (NASDAQ:EXEL) reported promising interim data from an ongoing phase 2 trial of XL184 in patients with recurrent glioblastoma (GB), the most common and aggressive form of brain cancer. D ... more

In a large study of patients with newly diagnosed glioblastoma, researchers have shown that any resection volume above 78% can confer a survival benefit. Medscape Medical News ... more

Medical Researchers at the University of Alberta have reported evidence that the orphan generic drug Dichloroacetate (DCA) may hold promise as potential therapy for perhaps the deadliest of all human ... more

Medical Researchers at the University of Alberta have reported evidence that the orphan generic drug Dichloroacetate (DCA) may hold promise as potential therapy for perhaps the deadliest of all human ... more

Contact: Noreen Remtulla noreen.remtulla@ualberta.ca 780-492-5986 University of Alberta Faculty of Medicine Dentistry Edmonton, AB – Medical Researchers at the University of Alberta reported today ... more

Medical researchers report evidence that the orphan generic drug dichloroacetate may hold promise as potential therapy for perhaps the deadliest of all human cancers: a form of brain cancer called gli ... more

Gliomas arise from the supporting cells of the brain, called the glia. These cells are subdivided into astrocytes, ependymal cells and oligodendroglial cells (or oligos). These tumors are graded from ... more

Advanced gliomas were shown to regress completely in rats after treatment with parvoviruses, and the animals survived significantly longer than untreated animals. Parvoviruses do not cause any disease ... more

Contact: Dr. Sibylle Kohlstaedt s.kohlstaedt@dkfz.de Helmholtz Association of German Research Centres Complete regression of malignant brain tumors after treatment with parvoviruses Particular parvovi ... more

Adult glioblastoma continues to be a difficult disease to treat, so healthcare professionals must have the most up-to-date information regarding optimal methods for diagnostic imaging and treatment of ... more

Contact: Jessica Winter Winter.63@osu.edu 614-292-3769 Ohio State University COLUMBUS, Ohio - - Researchers have developed a way to enhance how brain tumors appear in MRI scans and during surgery, mak ... more

Contact: Judith Schwartzbaum schwartzbaum.1@osu.edu 614-293-3878 Ohio State University COLUMBUS, Ohio – A new study links progression of a lethal type of brain tumor with reduced expression of more t ... more

Pharmacyclics, Inc. (Nasdaq: PCYC) announced multiple presentations covering its Btk and HDAC programs at the American Association for Cancer Research (AACR) 2010 Annual Meeting being held April 17-21 ... more

A study conducted by a collaborative team led by researchers from the University of Southern California (USC) may lead to better insight into the clinical outcome for some patients with a particularly ... more

Contact: Leslie Ridgeway leslie.ridgeway@usc.edu 323-442-2823 University of Southern California Study identifies patients with longer-than-expected survival times Los Angeles, Calif., April 15, 2010— ... more

Glioblastoma is a guileful enemy. While most of the brain tumor can often be removed surgically, in virtually every case the tumor reappears. One reason for this is that sporadic, infiltrative tumor c ... more

Contact: Caroline Arbanas arbanasc@wustl.edu 314-286-0109 Washington University School of Medicine Using powerful DNA sequencing technology to decode the genomes of cancer patients, scientists at Wash ... more

Glioblastoma can often be removed surgically, but the brain tumor often reappears, because some tumor cells remain in the brain. Researchers have now subjected these "forgotten" cells to closer scruti ... more

Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Ced ... more

Scientists have shown for the first time that malignant brain tumors arise directly from brain stem cells. Overproduction of the protein Tlx in mice stimulates the development of malignant brain tumor ... more

By Mike Havrilla, mikehavRx.com According to NCI/NIH statistics, approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year (with a similar number estimated to occur ... more

The "cradle" of new neurons in the adult brain is well known. It is what is called the subventricular zone, a tissue structure lining the lateral ventricles. This is where neural or brain stem cells r ... more

A drug already in clinical trials to treat a variety of tumors shows a remarkable ability to shut down growth of glioblastoma in both laboratory cells and in animals, say researchers from Georgetown L ... more

Contact: Karen Mallet km463@georgetown.edu 215-514-9751 Georgetown University Medical Center The drug, now being tested in other cancers, provides new hope for treatment of glioblastoma Washington, DC ... more

A drug already in clinical trials to treat a variety of tumors shows a remarkable ability to shut down growth of glioblastoma in both laboratory cells and in animals, say researchers. In their experim ... more

Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. ... more

Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. ... more

Contact: Darrell E. Ward Darrell.Ward@osumc.edu 614-293-3737 Ohio State University Medical Center COLUMBUS, Ohio Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or d ... more

High energy levels cause glioblastoma cells to proliferate; low levels cause them to grow less and to migrate. This study discovered that a molecule called miR-451 coordinates this grow-or-go behavior ... more

Contact: JAMA/Archives Media Relations mediarelations@jama-archives.org 312-464-5262 JAMA and Archives Journals Many important clinical and basic scientific advances have been made in the past five ye ... more

Although Dendreon has been grabbing most of the cancer-vaccine buzz these days, there are other companies in this space that are achieving clinical success. One of these companies, ImmunoCellular Ther ... more

Contact: Vanessa Wasta wastava@jhmi.edu 410-955-1287 Johns Hopkins Medical Institutions Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells ... more

In mice, researchers discover new way to prevent recurrence of glioblastoma ... more

Contact: Krista Conger kristac@stanford.edu 650-725-5371 Stanford University Medical Center STANFORD, Calif. Glioblastoma is one of the most deadly human brain cancers. Radiation can temporarily shri ... more

Contact: Anita B. Hjelmeland hjelmea@ccf.org Public Library of Science Researchers at the Cleveland Clinic report the identification of a protein that is highly expressed in a subgroup of glioblastoma ... more

Glioblastoma is one of the most deadly human brain cancers. Radiation can temporarily shrink tumors, but they nearly always recur within weeks or months and few patients survive longer than two years ... more

Patients with glioblastoma multiforme (GBM), an extremely aggressive brain tumor, have a very poor prognosis. Despite high dose radiotherapy, 75% of patients die within two years, usually as a result ... more

Glioblastoma is one of the most deadly human brain cancers. Radiation can temporarily shrink tumors, but they nearly always recur within weeks or months and few patients survive longer than two years ... more

Patients with glioblastoma multiforme (GBM), an extremely aggressive brain tumor, have a very poor prognosis. Despite high dose radiotherapy, 75% of patients die within two years, usually as a result ... more

Researchers report the identification of a protein that is highly expressed in a subgroup of glioblastoma brain tumor cells and show that depletion of this protein increases the survival of mice with ... more

Glioblastoma is one of the most deadly human brain cancers. Radiation can temporarily shrink a tumor, but they nearly always recur within weeks or months and few patients survive longer than two years ... more

This year will be a busy one for CytRx, a biopharmaceutical company with a focus on cancer treatment. CytRx #8217;s pipeline includes three oncology drugs that have Phase II clinical studies planned f ... more

Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have reached a collaboration agreement with immatics Biotechnologies to trial their new trea ... more

Peregrine Pharmaceuticals, Inc. ( PPHM) reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel bra ... more

Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. ... more

In this program, an expert on brain tumors discusses the current perspectives and latest advances in the treatment of glioblastoma multiforme (GBM). Evidence-based guidelines for newly diagnosed as we ... more

Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. ... more

In this activity, experts discuss the latest clinical trial data on targeted and other new therapies for glioblastoma multiforme, assess the clinical implications of these data, and review some of the ... more

A phase III trial of enzastaurin for treatment of recurrent glioblastoma was stopped after an interim analysis showed it did not outperform lomustine. Reuters Health Information ... more

Pfizer Inc. (NYSE: PFE) and DxS (a wholly owned subsidiary of QIAGEN N.V.) (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) announced that they have entered into an agreement to develop a companion diag ... more

Pfizer Inc. (NYSE: PFE) and DxS (a wholly owned subsidiary of QIAGEN N.V.) (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) announced that they have entered into an agreement to develop a companion diag ... more

Cancer researchers at UCLA's Jonsson Comprehensive Cancer Center have performed the complete sequencing of the much-studied brain cancer cell line, U87, a discovery that may lead to target ... more

Contact: Kim Irwin kirwin@mednet.ucla.edu 310-206-2805 University of California - Los Angeles Study may result in new and more effective therapies Researchers at UCLA #8217;s Jonsson Comprehensive Can ... more

Success in mice with glioblastoma may someday lead to treatment for people, researchers say Source: HealthDay Related MedlinePlus Topic: Brain Cancer ... more

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumour, also suppress an immune system attack on the disease, scientists from the University of Texas M. D. A ... more

Each subtype has a different response to therapy, which could lead to personalized treatment and raises hopes for improving the currently poor prognosis. Medscape Medical News ... more

The most common form of brain cancer in adults, glioblastoma multiforme, probably is a set of diseases, rather than a single disease, U.S. researchers said on Tuesday. Source: Reuters Health ... more

New findings by researchers at UNC Lineberger Comprehensive Cancer Center suggest that the most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is probably not a single ... more

The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by The Cancer ... more

Health News of the Day is a daily summary made from the selected links I post on Twitter. It is in a bullet points format with links to the original sources which include 350 RSS feeds that produce ab ... more

New findings by researchers at UNC Lineberger Comprehensive Cancer Center suggest that the most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is probably not a single ... more

The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by The Cancer ... more

Contact: Nancy Cawley Jean njean@lifespan.org Lifespan Achieved a 25 percent cure rate for gliobastoma in animal model; call for trials to begin in humans Providence, RI New research at Rhode Island ... more

The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by the Cancer ... more

The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by The Cancer ... more

The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by the Cancer ... more

Glioblastoma (GBM), the brain cancer better known for having killed Senator Ted Kennedy a few months ago, is the most aggressive and lethal of all brain tumours. But a collaboration between researcher ... more

Glioblastoma (GBM), the brain cancer better known for having killed Senator Ted Kennedy a few months ago, is the most aggressive and lethal of all brain tumours. But a collaboration between researcher ... more

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. An ... more

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. An ... more

Contact: Scott Merville smerville@mdanderson.org 713-792-0661 University of Texas M. D. Anderson Cancer Center M. D. Anderson researchers discover mechanism that helps glioblastomas evade attack HOUST ... more

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists have found. ... more

Immunocellular Therapeutics, a biotechnology company specializing in immune-based cancer treatments, presented Wednesday at the OneMedForum in San Francisco. The Los Angeles-based company discussed it ... more

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as w ... more

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as w ... more

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as w ... more

Geron Corporation (Nasdaq:GERN) announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, imetelstat (GRN163L), inhibited telomerase activity and reduced tumor si ... more

Geron Corporation (Nasdaq:GERN) announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, imetelstat (GRN163L), inhibited telomerase activity and reduced tumor si ... more

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center ha ... more

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center ha ... more

US researchers have completed two preclinical studies, one on isolated human cells and the other on rodents, that concluded an experimental breast and lung cancer drug shows promise against prostate ... more

US researchers have completed two preclinical studies, one on isolated human cells and the other on rodents, that concluded an experimental breast and lung cancer drug shows promise against prostate ... more

Therasis Co-Founder, Andrea Califano, Ph.D., and Wei Keat Lim, Ph.D., Head of Computational Systems Biology at Therasis, along with a team of scientists at Columbia University, have reported in the jo ... more

Therasis Co-Founder, Andrea Califano, Ph.D., and Wei Keat Lim, Ph.D., Head of Computational Systems Biology at Therasis, along with a team of scientists at Columbia University, have reported in the jo ... more

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center ha ... more

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers have found in two preclinical studie ... more

Contact: Aline McKenzie aline.mckenzie@utsouthwestern.edu 214-648-3404 UT Southwestern Medical Center DALLAS Jan. 4, 2010 An experimental drug currently being tested against breast and lung cancer s ... more

Co-Founder, Andrea Califano, Ph.D., and Wei Keat Lim, Ph.D., Head of Computational Systems Biology at Therasis, along with a team of scientists at Columbia University, have reported in the journal Nat ... more

Biomedical researchers at the University of Central Florida have found a protein that could hold the key to treating one of the most common and aggressive brain tumors in adults. Glioblastoma multifor ... more

Co-Founder, Andrea Califano, Ph.D., and Wei Keat Lim, Ph.D., Head of Computational Systems Biology at Therasis, along with a team of scientists at Columbia University, have reported in the journal Na ... more

Biomedical researchers at the University of Central Florida have found a protein that could hold the key to treating one of the most common and aggressive brain tumors in adults. Glioblastoma multifor ... more

Biomedical researchers have found a protein that could hold the key to treating one of the most common and aggressive brain tumors in adults. Glioblastoma multiforme, the type of malignant brain tumor ... more

Two newly discovered genes may act as master control switches in the progression of the most aggressive form of brain cancer, glioblastoma, a study shows. ... more

Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. ... more

In this program, an expert on brain tumors discusses the current perspectives and latest advances in the treatment of glioblastoma multiforme (GBM). Evidence-based guidelines for newly diagnosed as we ... more

Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. ... more

In this activity, experts discuss the latest clinical trial data on targeted and other new therapies for glioblastoma multiforme, assess the clinical implications of these data, and review some of the ... more

David Collingridge discusses research articles on prophylactic cranial irradiation for small-cell lung cancer, and the addition of temozolomide to radiotherapy for treating glioblastoma. ... more

Contact: Elizabeth Streich cumcnews@columbia.edu 212-305-3900 Columbia University Medical Center Discovery made using new systems biology method, which enabled the scientists to pinpoint the genes fro ... more

Contact: Zenaida Gonzalez Kotala zkotala@mail.ucf.edu 407-823-6120 University of Central Florida Biomedical researchers at the University of Central Florida have found a protein that could hold the ke ... more

Contact: Kim Irwin kirwin@mednet.ucla.edu 310-206-2805 University of California - Los Angeles Inhibiting fatty acid synthesis in brain cancer cells may offer a new option to treat about 50 percent of ... more

MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® th ... more

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma multiforme (GBM), ... more

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma multiforme (GBM), ... more

MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® th ... more

Cancer researchers developed a tumor-attacking virus that kills brain-tumor cells and blocks tumor blood-vessel growth. The research shows that viruses designed to kill cancer cells -- oncolytic virus ... more

Contact: Oihane Lakar oihane@elhuyar.com 0034-943-363-040 Elhuyar Fundazioa The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunother ... more

By Mike Havrilla, ProActive Newsroom Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille ... more

Roche announced today that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting the initial assessment of medicinal products that have been filed for marketin ... more

Apogenix GmbH, a biopharmaceutical company developing novel drugs for malignant and inflammatory diseases, announced that the European Medicines Agency adopted a positive opinion on orphan medicinal p ... more

Apogenix GmbH, a biopharmaceutical company developing novel drugs for malignant and inflammatory diseases, announced that the European Medicines Agency adopted a positive opinion on orphan medicinal ... more

By Mike Havrx ProActive Newsroom Protox Therapeutics (TSX: PRX.TO) (OTC: PTXRF.PK) applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on ... more

MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Na ... more

MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Na ... more

MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Na ... more

Researchers from University Hospitals Case Medical Center report promising results from a cutting-edge research study that treated the aggressive brain tumors glioblastoma multiforme (GBM) using a nov ... more

Researchers from University Hospitals Case Medical Center report promising results from a cutting-edge research study that treated the aggressive brain tumors glioblastoma multiforme (GBM) using a nov ... more

Researchers report promising results from a cutting-edge research study that treated the aggressive brain tumors glioblastoma multiforme using a novel type of imaging called MR spectroscopy coupled wi ... more

By Mike Havrilla MikeHavRx.com NeoPharm (OTC: NEOL.PK) is an emerging bio-pharmaceutical company focused on the development of anti-cancer agents based on two proprietary technology platforms that in ... more

Roche today announced that an analysis of the phase II BRAIN study of bevacizumab (Avastin®) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblas ... more

MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its pro ... more

Roche today announced that an analysis of the phase II BRAIN study of bevacizumab (Avastin®) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblas ... more

In an advance toward better treatments for the most serious form of brain cancer, scientists in Illinois are reporting development of the first nanoparticles that seek out and destroy brain cancer cel ... more

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demo ... more

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demo ... more

The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a ... more

The recent death of Senator Ted Kennedy has focused new attention on brain cancer.  Glioblastoma multiforme (GBM), the aggressive brain tumor that took Sen. Kennedy #8217;s life, is one of the deadli ... more

Researchers funded by the National Institutes of Health have found that the activity of a protein in brain cells helps stimulate the spread of an aggressive brain cancer called glioblastoma multiforme ... more

Researchers funded by the National Institutes of Health have found that the activity of a protein in brain cells helps stimulate the spread of an aggressive brain cancer called glioblastoma multiforme ... more

Researchers find that the STAT3 gene regulates the growth of cancer stem cells in the brain cancer Glioblastoma multiforme. This evidence is consistent with the controversial theory that a minority of ... more

Two forms of skin and brain cancer respond very poorly to chemotherapy and radiation: melanoma and glioblastoma multiforme brain cancer. Both are the focus of an intensive effort in the department ... more

Cancer researchers have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell and animal studies. Glioblastoma is the deadliest of brain canc ... more

Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell ... more

Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell ... more

A new strategy proposed by researchers at Dartmouth Medical School and Amtek, Hanover, NH may treat tumors that do not respond to conventional treatment. The study, which was published on May 29th in ... more

The brain tumor afflicting Sen. Edward Kennedy -- a glioblastoma -- is the most aggressive form of brain cancer. But scientists have discovered the tumor's vulnerability. They have identified a networ ... more

The Derrick L. Davis Forsyth Regional Cancer Center at Forsyth Medical Center is participating in a national trial of the experimental drug Avastin to treat glioblastoma, a fast-growing tumor of the b ... more

The Derrick L. Davis Forsyth Regional Cancer Center at Forsyth Medical Center is participating in a national trial of the experimental drug Avastin to treat glioblastoma, a fast-growing tumor of the b ... more

Mayo Clinic researchers and colleagues at the University of California San Francisco (UCSF) have found a connection between DNA alterations on human chromosome 9 and aggressive brain cancer known as g ... more

Mayo Clinic researchers and colleagues at the University of California San Francisco (UCSF) have found a connection between DNA alterations on human chromosome 9 and aggressive brain cancer known as g ... more

Scientists have found a connection between DNA alterations on human chromosome 9 and aggressive brain cancer known as glioblastoma. ... more

A specific biomarker, a protein released by dying tumor cells, has been identified as an effective tool in an animal model to gauge the response to a novel gene therapy treatment for glioblastoma muli ... more

A specific biomarker, a protein released by dying tumor cells, has been identified as an effective tool in an animal model to gauge the response to a novel gene therapy treatment for glioblastoma muli ... more

A specific biomarker, a protein released by dying tumor cells, has been identified as an effective tool in an animal model to gauge the response to a novel gene therapy treatment for glioblastoma muli ... more

St. Joseph's Hospital and Medical Center in Phoenix has partnered with Castle Biosciences, Inc. to provide the nation's first genomics-based test for patients suffering from glioblastoma multiforme, ... more

St. Joseph's Hospital and Medical Center in Phoenix has partnered with Castle Biosciences, Inc. to provide the nation's first genomics-based test for patients suffering from glioblastoma multiforme, ... more

A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumo ... more

A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumo ... more

A new biomarker may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib. ... more

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that researchers will present data at the SNM 2009 Annual Meeting showing that its brain cancer agent Cotara(R) specifically localizes to brain ... more

The U.S. Food and Drug Administration recently approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme (GBM) when this form of brain cancer continues to progress following standa ... more

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company, presented promising clinical data from a Phase I trial evaluating ICT-107, the company's dendritic cell-based cancer va ... more

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company, presented promising clinical data from a Phase I trial evaluating ICT-107, the company's dendritic cell-based cancer va ... more

Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) reported encouraging data from an ongoing phase 2 trial of XL184 in patients with previously treated glioblastoma multiforme (G ... more

Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) reported encouraging data from an ongoing phase 2 trial of XL184 in patients with previously treated glioblastoma multiforme (G ... more

- An experimental drug derived from cottonseeds shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer, said researchers at the University ... more

An experimental drug derived from cottonseed shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer, said researchers at the University of ... more

An experimental drug derived from cottonseed shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer, said researchers at the University of ... more

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, provided an update ... more

An experimental compound showed good results for months in patients with glioblastoma multiforme, researchers say. After undergoing other treatments, including surgery, chemotherapy and radiation, the ... more

Source: American Cancer Society ... more

New research from the University of Virginia Health System shows that, when combined, two emerging medical technologies hold significant promise for treating the most deadly and devastating form of br ... more

New research from the University of Virginia Health System shows that, when combined, two emerging medical technologies hold significant promise for treating the most deadly and devastating form of br ... more

A new device that delivers high-intensity laser energy into the brain has been cleared for investigational use in patients with glioblastoma multiforme. Medscape Medical News ... more

Eligible patients with newly diagnosed glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, are enrolling in the ACT III clinical trial of a vaccine called CDX-110, whic ... more

Eligible patients with newly diagnosed glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, are enrolling in the ACT III clinical trial of a vaccine called CDX-110, whic ... more

The U.S. Food and Drug Administration recently approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme (GBM) when this form of brain cancer continues to progress following standa ... more

The U.S. Food and Drug Administration recently approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme (GBM) when this form of brain cancer continues to progress following standa ... more

Ongoing ACT III Clinical Research Trial Studies CDX-110 Vaccine; Aimed at Training Immune System to Kill Cancer Cells > NewYork-Presbyterian Hospital, Weill Cornell Medical College and Columbia Uni ... more

The FDA (Food and Drug Administration, USA) approved Avastin (bevacizumab) for patients with GBM (glioblastoma multiforme) whose cancer carries on progressing after standard therapy. GBM is a rapidly ... more